Phase I Trial to Evaluate the Safety of Intralesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma

By afschroeder • July 15, 2025

Wang CJ, Bang A, Chowdhury S, Leslie KS, Lang UE, Shimoda M, Henrich TJ, Hoh R, Deeks SG, Wang C, Deitchman AN, Couey P, Maurer T. Phase I Trial to Evaluate the Safety of Intralesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma. JCO Oncol Adv. 2025 Jul 7;2(1):e2400098. doi: 10.1200/OA-24-00098. PMID: 40655531; PMCID: PMC12244976.

Tags: Dermatology, Publications, Resident

Epigenetic age and accelerated aging phenotypes: a tumor biomarker for predicting colorectal cancer

Jung SY, Pellegrini M, Tan X, Yu H. Epigenetic age and accelerated aging phenotypes: a tumor biomarker for predicting colorectal cancer. Aging (Albany NY). 2025[...]

Macrophage-derived Spp1 promotes intramuscular fat in dystrophic muscle

Farahat PK, Kumagai-Cresse C, Aragón RL, Ma F, Amakor JK, Espinoza A, Kramerova I, Jimenez RJ, Smith BM, Perez J, Crosbie RH, Nagendra AH, McCourt-Towner[...]

AI-Assisted Billing in Dermatologic Surgery: Evaluating ChatGPT’s and Gemini’s Accuracy in CPT Code Assignment

Modiri O, Ebriani J, Jairath N, Lewin J. AI-Assisted Billing in Dermatologic Surgery: Evaluating ChatGPT's and Gemini's Accuracy in CPT Code Assignment. Dermatol Surg. 2025[...]